2010
DOI: 10.1007/s11307-010-0400-3
|View full text |Cite
|
Sign up to set email alerts
|

A Low Molecular Weight Folate Receptor Targeted Contrast Agent for Magnetic Resonance Tumor Imaging

Abstract: These data support the use of FR-targeted small molecular weight MRI contrast agents for tumor imaging in vivo.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
27
0

Year Published

2012
2012
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 31 publications
(27 citation statements)
references
References 33 publications
0
27
0
Order By: Relevance
“…14,15 The distribution of Pt, Se, 14 Gd, and Lu 18 has also been mapped following in vivo administration of respective metal containing compounds.…”
mentioning
confidence: 99%
“…14,15 The distribution of Pt, Se, 14 Gd, and Lu 18 has also been mapped following in vivo administration of respective metal containing compounds.…”
mentioning
confidence: 99%
“…A range of other 'targeted' contrast agents are under development for both MRI and ultrasound imaging. [33][34][35] While there are numerous studies that have used DCE-MRI to obtain tumor information based on vascular differences, 36,37 our results suggest that targeted contrast agents that interact directly with tissues could yield significant functional information if combined with dynamic contrast approaches.…”
Section: Discussionmentioning
confidence: 75%
“…Folate-conjugated monomeric contrast agent 6 (Fig. 2) has a low relaxivity of 1.28 mM −1 s −1 (4.7 T and aqueous solution) [29]. In vitro studies of 6 with human folate-receptor-positive ovarian carcinoma (IGROV-1) cell lines did not produce signal enhancement; however, inductively coupled plasma-mass spectrometry results with competitive binding experiments confirmed the uptake of 6 by the cells.…”
Section: The Conjugation Strategymentioning
confidence: 99%